| DAT | |
|---|---|
| Specialty | oncology |
DAT in the context of chemotherapy is an acronym that means a chemotherapy regimen most often used as an induction regimen in acute myelogenous leukemia, usually for those who are refractory to the standard "7+3" induction regimen or who has relapsed. But this regimen also can be used as primary, first-line induction therapy.
The DAT regimen consists of:
- (D)aunorubicin - an anthracycline antibiotic that is able to intercalate DNA, thus disrupting cell division and preventing mitosis;
- (A)ra-C (cytarabine) - an antimetabolite;
- (T)hioguanine - another antimetabolite.[1]
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| Ara-C (cytarabine) | 200 mg/m2 | IV push every 12 hours in 2 divided doses (100 mg/m2 each) | Days 1-10 |
| Daunorubicin | 50 mg/m2 | IV slow push | Days 1, 3 and 5 |
| Thioguanine | 200 mg/m2 | PO every 12 hours in 2 divided doses (100 mg/m2 each) | Days 1-10 |
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.